In vitro characterization of the imaging and therapeutic agent showed low nanomolar binding to EGFR-positive colorectal cancer and breast cancer cells with (DLD-1, SNU-C2B, SW620) or without (HT-29 and MDA-MB-231) mutations in KRAS. This evidence concerns the gene KRAS and breast carcinoma.